British Journal of Cancer

Article	Citations
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy	623
Cancer health disparities in racial/ethnic minorities in the United States	452
Deep learning in cancer pathology: a new generation of clinical biomarkers	302
The lingering mysteries of metastatic recurrence in breast cancer	268
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond	236
Achieving clinical success with BET inhibitors as anti-cancer agents	213
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression	183
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance	162
Insights into the role of sialylation in cancer progression and metastasis	137
Tumour treating fields therapy for glioblastoma: current advances and future directions	134
How promising is phototherapy for cancer?	128
Treatment strategies for breast cancer brain metastases	119
EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures	116
Promises and challenges of adoptive T-cell therapies for solid tumours	116
Autophagy as a therapeutic target in pancreatic cancer	108
Cysteine metabolic circuitries: druggable targets in cancer	106
Mutational drivers of cancer cell migration and invasion	106
The untapped potential of ascites in ovarian cancer research and treatment	103
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials	101
Radiomics and radiogenomics in gliomas: a contemporary update	97
The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO)	86
Endocytosis: a pivotal pathway for regulating metastasis	80
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial	79
The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020	77
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience	77

Artificial intelligence in oncology: current applications and future perspectives	77
Metabolic reprogramming in prostate cancer	76
Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)	74
The gut microbiome: what the oncologist ought to know	74
Cell-free DNA analysis in current cancer clinical trials: a review	74
Cancer immunotherapy: it’s time to better predict patients’ response	72
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study	70
Radiation-induced bystander and abscopal effects: important lessons from preclinical models	70
Severity of COVID-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project	68
Artificial Intelligence-based methods in head and neck cancer diagnosis: an overview	68
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma	67
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma	64
Towards decoding the coupled decision-making of metabolism and epithelial-to-mesenchymal transition in cancer	64
Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration	64
The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials	64
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer	63
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours	63
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours	62
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours	62
Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer	61
Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy	61
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours	61
Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer	60
Biomarkers of response to PD-1 pathway blockade	60
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer	57
Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects	57
The current treatment landscape in the UK for stage III NSCLC	55
Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence	55
Roles of mitochondria in the hallmarks of metastasis	54
Long non-coding RNAs are involved in alternative splicing and promote cancer progression	54
Adoption of artificial intelligence in breast imaging: evaluation, ethical constraints and limitations	54
Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)	52
Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma	52
Detection of clustered circulating tumour cells in early breast cancer	52
Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma	52
The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis	52
Current concepts in tumour-derived organoids	51
Cannabinoids as anticancer drugs: current status of preclinical research	51
Cancer metastasis as a non-healing wound	51
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer	50
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model	50
The current status of risk-stratified breast screening	49
Cancer cachexia: a nutritional or a systemic inflammatory syndrome?	49
Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer	48
E2F7−EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression	48
Effects of cancer screening restart strategies after COVID-19 disruption	47
The fibrotic and immune microenvironments as targetable drivers of metastasis	47
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?	47
Vascular normalisation as the stepping stone into tumour microenvironment transformation	47
Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies	47

Non-coding RNAs as liquid biopsy biomarkers in cancer	46
Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma	45
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor	45
Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage III colorectal cancer patients	44
Increases in arm volume predict lymphoedema and quality of life deficits after axillary surgery: a prospective cohort study	44
Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK	44
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site	44
Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia	44
First results from five multidisciplinary diagnostic centre (MDC) projects for non-specific but concerning symptoms, possibly indicative of cancer	43
Overcoming the challenges associated with CD3+ T-cell redirection in cancer	43
Tumour-infiltrating lymphocytes: from prognosis to treatment selection	43
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer	42
Association of obesity status and metabolic syndrome with site-specific cancers: a population-based cohort study	42
Let the question determine the methods: descriptive epidemiology done right	42
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges	42
COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic	41
MicroRNA-17-5p regulates EMT by targeting vimentin in colorectal cancer	41
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models	41
Tumour acidosis evaluated in vivo by MRI-CEST pH imaging reveals breast cancer metastatic potential	41
Diagnostic performance of a faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: an evaluation in the South West of England	41
Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research	41
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab	40
Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)	40
Mitochondrial oxidative phosphorylation in cutaneous melanoma	40
Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials	40
Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis	40
Impact of HPV vaccination on cervical screening performance: a population-based cohort study	39
Novel urinary protein biomarker panel for early diagnosis of gastric cancer	39
Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade	39
IQGAP1 promotes anoikis resistance and metastasis through Rac1-dependent ROS accumulation and activation of Src/FAK signalling in hepatocellular carcinoma	39
Cancer-inducing niche: the force of chronic inflammation	39
Advances in the curative management of oesophageal cancer	38
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?	38
Current and novel therapeutic opportunities for systemic therapy in biliary cancer	38
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry	38
Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses	38
Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling	38
A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency	38
Squeezing through the microcirculation: survival adaptations of circulating tumour cells to seed metastasis	38
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours	38
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models	38
Tumour budding and its clinical implications in gastrointestinal cancers	37
Targeting NQO1/GPX4-mediated ferroptosis by plumbagin suppresses in vitro and in vivo glioma growth	37
Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma	37
Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis	37
Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic	37
Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in London	37
Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer	37
Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer	37
Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer	37
Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts	37
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events	37
Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR	36
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges	36
UK Biobank: a globally important resource for cancer research	36
Emerging immunotherapies for metastasis	36
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors	35
Bone marrow niches in the regulation of bone metastasis	35
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy	35
Supplemental breast cancer-screening ultrasonography in women with dense breasts: a systematic review and meta-analysis	35
New tools to prevent cancer growth and spread: a ‘Clever’ approach	35
Differences in cancer incidence by broad ethnic group in England, 2013–2017	34
Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines	34
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium	34
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150	34
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy	34
An urgent call to raise the bar in oncology	34
EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-β/SMAD signalling	33
Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights	33
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design	33
Mammographic microcalcifications and risk of breast cancer	33
Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank	33
Ultra-processed foods and cancer risk: from global food systems to individual exposures and mechanisms	32
MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data	32
Genkwadaphnin inhibits growth and invasion in hepatocellular carcinoma by blocking DHCR24-mediated cholesterol biosynthesis and lipid rafts formation	32
SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis	32
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?	32
The association of diabetes with risk of prostate cancer defined by clinical and molecular features	32
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08	31
Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin	31

Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity	31
Pancreatic cancer cachexia: three dimensions of a complex syndrome	31
Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project	31
The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer	31
The risk of contralateral breast cancer: a SEER-based analysis	31
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer	31
Prognostic significance of pre- and post-operative tumour markers for patients with gastric cancer	31
Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study	31
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer	31
Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy	31
Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways	30
Differential association of CD68+ and CD163+ macrophages with macrophage enzymes, whole tumour gene expression and overall survival in advanced melanoma	30
Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature	30
At the dawn: cell-free DNA fragmentomics and gene regulation	30
Omental adipocytes promote peritoneal metastasis of gastric cancer through the CXCL2–VEGFA axis	30
COVID-19 vaccine race: watch your step for cancer patients	30
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial	30
Bromodomain inhibitors a decade later: a promise unfulfilled?	30
Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer	30
The relationships between systemic cytokine profiles and inflammatory markers in colorectal cancer and the prognostic significance of these parameters	29
Hypoxia and its therapeutic possibilities in paediatric cancers	29
Evaluation of p16INK4a expression as a single marker to select patients with HPV-driven oropharyngeal cancers for treatment de-escalation	29
Cancer survivorship, excess body fatness and weight-loss intervention—where are we in 2020?	29
Genomic landscape of pleural and peritoneal mesothelioma tumours	29
CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms	29
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer	29
Tumour-derived CSF2/granulocyte macrophage colony stimulating factor controls myeloid cell accumulation and progression of gliomas	29
Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway	29
Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data	29
Oral antibiotic use and early-onset colorectal cancer: findings from a case-control study using a national clinical database	29
New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer	29
Tumour neoantigen mimicry by microbial species in cancer immunotherapy	28
Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer	28
Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy	28
Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom	28
Porphyromonas gingivalis infection exacerbates oesophageal cancer and promotes resistance to neoadjuvant chemotherapy	28
G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer	28
Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer	28
Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges	28
UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology	28
Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework	28
Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis	28
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	28
Genomic control of metastasis	28
The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation	27
Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer	27
Antibiotic use and risk of colorectal cancer: a systematic review and dose–response meta-analysis	27
Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case–control study nested within the French E3N cohort	27
Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma	27
TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma	27
Incidence trends for twelve cancers in younger adults—a rapid review	27
Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations	27
T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting	27
Fruit and vegetable consumption and incident breast cancer: a systematic review and meta-analysis of prospective studies	27
Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank	26
Cell-free DNA technologies for the analysis of brain cancer	26
Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data	26
A systematic review of microbial markers for risk prediction of colorectal neoplasia	26
miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition	26
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities	26
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds	26
Exosomal protein angiopoietin-like 4 mediated radioresistance of lung cancer by inhibiting ferroptosis under hypoxic microenvironment	26
Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy	26
APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer	26
The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study	26
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis	26
EGFR as a stable marker of prostate cancer dissemination to bones	26
Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status	26
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian ca	26
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them	26
CD8+ T cells inhibit metastasis and CXCL4 regulates its function	25
Unravelling similarities and differences in the role of circular and linear PVT1 in cancer and human disease	25
OXPHOS-dependent metabolic reprogramming prompts metastatic potential of breast cancer cells under osteogenic differentiation	25
Considering therapy-induced senescence as a mechanism of tumour dormancy contributing to disease recurrence	25
The significance of highlighting the oestrogen receptor low category in breast cancer	25
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response	25
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers	25
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer	25
CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt/β-catenin signalling pathway	25
IL-10 in glioma	25
Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer	25
Lactate concentration in breast cancer using advanced magnetic resonance spectroscopy	25
Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1	25
Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity	25
Metastasis: crosstalk between tissue mechanics and tumour cell plasticity	25
Circulating tumour cells in the -omics era: how far are we from achieving the ‘singularity’?	25
Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study	24
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles	24
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression	24
Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group	24
Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells	24
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours	24
Novel evidence for m6A methylation regulators as prognostic biomarkers and FTO as a potential therapeutic target in gastric cancer	24
Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients	24
Targeting obesity-related dysfunction in hormonally driven cancers	24